Please Wait
Applying Filters...
menu
    • menu
    Minakem delivers API, HPAPI, steroids & CDMO services for generics with FDA/GMP certification, regulatory know-how & proven success.

    Virtual Booth

    Contact Supplier

    Metrochem has been delivering customized volume & quality products to customers across the world, taking utmost care of their needs.

    Virtual Booth

    Contact Supplier

    HealthTech BioActives, leading globally in Flavonoids and Vitamin B12 Derivatives.

    Virtual Booth

    Contact Supplier

    Biophore is a research-driven global pharmaceutical company focused on niche APIs for the generic industry.

    Virtual Booth

    Contact Supplier

    Aspen API. More than just an API™

    Virtual Booth

    Contact Supplier

    FAMAR CDMO- From early development to commercial manufacturing.

    Virtual Booth

    Contact Supplier

    Menu

    Tinlarebant

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Belite Ends 2-Year Ph 3 Tinlarebant Trial in Stargardt Disease
    Belite Ends 2-Year Ph 3 Tinlarebant Trial in Stargardt Disease

    12 Sep 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/09/12/3149167/0/en/Belite-Bio-Announces-Completion-of-DRAGON-a-2-Year-Phase-3-Trial-of-Oral-Tinlarebant-in-the-Treatment-of-Stargardt-Disease.html

    GLOBENEWSWIRE
    12 Sep 2025
    Share Share
    Belite Bio Completes Enrollment in Global Phase 3 PHOENIX Trial
    Belite Bio Completes Enrollment in Global Phase 3 PHOENIX Trial

    02 Jul 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/07/02/3108920/0/en/Belite-Bio-Announces-Completion-of-Enrollment-in-the-Pivotal-Global-Phase-3-PHOENIX-Trial-Evaluating-Oral-Tinlarebant-in-Geographic-Atrophy.html

    GLOBENEWSWIRE
    02 Jul 2025
    Share Share
    Belite Gets Breakthrough For Tinlarebant In Stargardt Diseases
    Belite Gets Breakthrough For Tinlarebant In Stargardt Diseases

    21 May 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/05/21/3085441/0/en/Belite-Bio-Announces-FDA-Granting-of-Breakthrough-Therapy-Designation-for-Tinlarebant-for-the-Treatment-of-Stargardt-Disease.html

    GLOBENEWSWIRE
    21 May 2025
    Share Share
    Belite’s Ph 3 Trial Shows Tinlarebant Benefits In Stargardt Disease
    Belite’s Ph 3 Trial Shows Tinlarebant Benefits In Stargardt Disease

    27 Feb 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/02/27/3033536/0/en/Belite-Bio-Announces-Interim-Analysis-Results-from-the-Pivotal-Global-Phase-3-DRAGON-trial-of-Tinlarebant-in-Adolescent-Stargardt-Disease-Subjects.html

    GLOBENEWSWIRE
    27 Feb 2025
    Share Share
    Belite Bio Announces Doses First Patient In DRAGON II Trial
    Belite Bio Announces Doses First Patient In DRAGON II Trial

    10 Sep 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/09/10/2943626/0/en/Belite-Bio-Announces-First-Patient-Dosed-in-Phase-2-3-DRAGON-II-Trial-of-Tinlarebant-for-the-Treatment-of-Stargardt-Disease.html

    GLOBENEWSWIRE
    10 Sep 2024
    Share Share
    Belite Bio Reports Q2 2024 Results And Corporate Update
    Belite Bio Reports Q2 2024 Results And Corporate Update

    09 Aug 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/08/09/2927935/0/en/Belite-Bio-Reports-Second-Quarter-2024-Financial-Results-and-Provides-a-Corporate-Update.html

    GLOBENEWSWIRE
    09 Aug 2024
    Share Share